TRANSPLANTATION AND CELLULAR ENGINEERING: Prolonged isolated red blood cell transfusion requirement after allogeneic blood stem cell transplantation: identification of patients at risk

BACKGROUND: Delayed donor red blood cell chimerism (DRCC), pure red blood cell aplasia (PRCA), and autoimmune hemolytic anemia (AIHA) are poorly documented complications after hematopoietic cell transplantation (HCT). The clinical variable “prolonged isolated red blood cell transfusion requirement” (PRTR) was evaluated as a trigger for an extended diagnostic workup.

[1]  A. Gratwohl,et al.  Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins , 2009, Haematologica.

[2]  H. Greinix,et al.  Prophylactic red blood cell exchange for prevention of severe immune hemolysis in minor ABO‐mismatched allogeneic peripheral blood progenitor cell transplantation after reduced‐intensity conditioning , 2007, Transfusion.

[3]  G. Helbig,et al.  Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies , 2007, Annals of Hematology.

[4]  N. Puig,et al.  Autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation in adult patients , 2007, Bone Marrow Transplantation.

[5]  J. P. McCoy,et al.  Persistence of recipient plasma cells and anti‐donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non‐myeloablative haematopoietic cell transplantation , 2005, British journal of haematology.

[6]  J. Sierra,et al.  Impact of ABO incompatibility on allogeneic peripheral blood progenitor cell transplantation after reduced intensity conditioning , 2004, Transfusion.

[7]  J. Neglia,et al.  Autoimmune haemolytic anaemia complicating haematopoietic cell transplantation in paediatric patients: high incidence and significant mortality in unrelated donor transplants for non‐malignant diseases , 2004, British journal of haematology.

[8]  A. Barrett,et al.  Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. , 2001, Blood.

[9]  S Mackinnon,et al.  Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  S. Klaesson.  Clinical use of rHuEPO in bone marrow transplantation , 1999, Medical oncology.

[11]  J. Connors,et al.  Prolonged erythroid aplasia after major ABO-mismatched transplantation for chronic myelogenous leukemia. , 1998, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  M. Laffan,et al.  Late onset haemolysis and red cell autoimmunisation after allogeneic bone marrow transplant , 1997, Bone Marrow Transplantation.

[13]  J. Gottschall,et al.  Autoimmune hemolytic anemia following T cell-depleted allogeneic bone marrow transplantation. , 1996, Bone marrow transplantation.

[14]  M. V. van Tol,et al.  The origin of IgG production and homogeneous IgG components after allogeneic bone marrow transplantation. , 1996, Blood.

[15]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[16]  M. Caligiuri,et al.  Autoimmune pancytopenia following allogeneic bone marrow transplantation. , 1990, Bone marrow transplantation.

[17]  R. Buckley,et al.  Development of multiple monoclonal serum immunoglobulins (multiclonal gammopathy) following both HLA-identical unfractionated and T cell-depleted haploidentical bone marrow transplantation in severe combined immunodeficiency , 1990, Journal of Clinical Immunology.

[18]  L. Hammarström,et al.  IgA2 ALLOTYPES DETERMINED BY RESTRICTION FRAGMENT LENGTH POLYMORPHISM IN IgA DEFICIENCY RE‐EXPRESSION OF THE SILENT A2m(2) ALLOTYPE IN THE CHILDREN OF IgA‐DEFICIENT PATIENTS , 1987, Journal of immunogenetics.

[19]  L. Hammarström,et al.  Development of IgG2 deficiency in a bone-marrow-transplanted patient. Implication for generation of the anticarbohydrate antibody repertoire in subclass-deficient individuals. , 1987, Transplantation.

[20]  L. Hammarström,et al.  Frequent occurrence of monoclonal gammopathies with an imbalanced light-chain ratio following bone marrow transplantation. , 1987, Transplantation.

[21]  R. Storb,et al.  IMMUNOGLOBULIN PRODUCTION OF DONOR ORIGIN AFTER MARROW TRANSPLANTATION FOR ACUTE LEUKEMIA OR APLASTIC ANEMIA , 1978, Transplantation.

[22]  F. Brema,et al.  A to O Bone Marrow Transplantation in Severe Aplastic Anaemia: Dynamics of Blood Group Conversion and Demonstration of Early Dyserythropoiesis in the Engrafted Marrow , 1977, British journal of haematology.

[23]  W. Kidney.  Autoimmune haemolytic anaemia. , 1967, Journal of the Irish Medical Association.

[24]  R. Hagedoorn,et al.  Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. , 2007, Blood.

[25]  R. Soutar,et al.  Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. , 1996, British journal of haematology.